VemurafenibFever following off-label use

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 1998卷 / 1期

关键词：

D O I：

10.1007/s40278-024-54306-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：462 / 462

相关论文

共 50 条

[31] TocilizumabNeutropenia following off-label use: case report
[J]. Reactions Weekly, 2021, 1853 (1) : 446 - 446
[32] DaratumumabHypogammaglobulinemia following off-label use: case report
[J]. Reactions Weekly, 2019, 1744 (1) : 111 - 111
[33] PrednisoloneInefficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1910 (1) : 405 - 405
[34] SunitinibCardiomyopathy following off-label use: case report
[J]. Reactions Weekly, 2023, 1971 (1) : 240 - 240
[35] GlibenclamideHypoglycaemia following off-label use: case report
[J]. Reactions Weekly, 2021, 1857 (1) : 162 - 162
[36] NivolumabDiffuse maculopapular rash following off-label use
[J]. Reactions Weekly, 2024, 2006 (1) : 538 - 538
[37] RisperidonePancreatitis following off-label use: case report
[J]. Reactions Weekly, 2022, 1934 (1) : 378 - 378
[38] SirolimusNeutropenia following off-label use: case report
[J]. Reactions Weekly, 2023, 1960 (1) : 394 - 394
[39] CyclophosphamideMyelosuppression following off-label use: case report
[J]. Reactions Weekly, 2020, 1835 (1) : 116 - 116
[40] DenosumabHypocalcaemia following off-label use: case report
[J]. Reactions Weekly, 2022, 1923 (1) : 178 - 178

← 1 2 3 4 5 →